ORIC News and Press, Oric Pharmaceuticals Inc. From 08/12/25

Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

Oric Pharmaceuticals Inc. (ORIC) is expected to report $-0.46 for Q2 2025

2025-08-06 07:58:52 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals: What It Takes To Be Best In Class

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The rising burden of cancer is poised to strain both healthcare systems and patient finances, especially as cases continue to climb. At the same time, signals out of Wa...

2025-06-11 16:30:04 ET Read the full article on Seeking Alpha For further details see: Oric Pharmaceuticals files to sell 19.23M shares of common stock by selling shareholders

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date...

2025-05-28 16:41:48 ET More on ORIC Pharmaceuticals ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals ...

Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA responses were observed across all ORIC-944 dose levels and at comparable ra...

Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital Pro forma cash and investments expected to fund ...